摘要
目的:评价奥氮平对难治性精神分裂症的疗效与不良反应。 方法:对难治性精神分裂症80例换用奥氮平治疗24周。用阳性症状和阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)及锥体外系副反应量表(ESRS)评定不良反应。 结果:PANSS量表总分及各分量表评分疗后均有显著下降。最常见的不良反应是体重增加。 结论:奥氮平对难治性精神分裂症疗效肯定,不良反应较轻。
Objective: To observe the clinical efficacy and side effects of olanzapine in the treatment of refractory schizophrenic patients. Method:Eighty inpatients with refractory schizophrenia were treated with olanzapine for 24 weeks. The positive and negative symptoms scale (PANSS) was used to evaluate the efficacy,while the treatment emergent symptoms scale (TESS) and the extrapyramidal symptom rating scale (ESRS) were used to assess the side effects. Results: After the treatment, the scores of PANSS and its subscales were significantly decreased. The main side effect was weight increment. Conclusion: Olanzapine is an effective and safe novel antipsychotic in the treatment of refractory schizophrenia. Its side effect is slight.
出处
《临床精神医学杂志》
2003年第1期24-25,共2页
Journal of Clinical Psychiatry
